CD86 and sarcoma: We assessed a panel of pediatric sarcoma cell lines, including OS (SJSA-1, U2OS), RMS (RD, RH30) and EwS (A673, TC32, TC71 and SKNMC) for their basal expression of the immunogenic surface markers CD86, CD83, PD-L1, ICAM-1, MHC-I and MHC-II in comparison to healthy donor-derived PBMCs.